Virus-associated chronic endometritis: treatment options

Abstract

Aim. To evaluate the effectiveness of Alloferon (Allokin-alfa) in the complex treatment of virus-associated chronic endometritis (CE) in patients with infertility, papillomavirus infection (PVI) persisting in the uterine cavity, and recurrent herpes-virus infection localized in the genital area.
 Materials and methods. A prospective (n=33) open randomized (2:1) study was conducted to assess the efficacy of Alloferon (Allokin-alfa) in the complex treatment of CE in patients with infertility, PVI, and recurrent herpes-virus infection, aged 25 to 37 years (median age 31 [29; 32.5] years). All patients received valacyclovir therapy at 500 mg once daily for 30 days from the day of randomization. Patients in the main group (n=21) simultaneously with the start of antiviral therapy received Allokin-alfa as 9 subcutaneous injections once every two days (one injection every other day). The uterine cavity microbiota of the patients was assessed 3 months after treatment, and histological and immunohistochemical studies of endometrial biopsy specimens were performed.
 Results. The microbiological data analysis showed HPV elimination in 71.4% vs 16.7% of patients in the alloferon and control groups, respectively (2 7.102, p=0.008). Also, in the main group, a significant decrease in the severity of CE (2 27.586, p0.001) and p16ink4a protein expression levels (2 6.17, p=0.013) were observed.
 Conclusion. In the treatment of virus-associated CE, the addition of alloferon to virus-suppressive therapy leads to higher rates of HPV elimination from the uterine cavity and significantly reduces the severity of CE.

Study of alloferon, a novel immunomodulatory antimicrobial peptide (AMP), and its analogues

“…Several studies utilized alloferon as the active ingredient in antiviral drugs to treat various viral infections. In a study conducted by Tapilskaya et al, alloferon (Allokin-alpha) was evaluated in the complex treatment of virus-associated chronic endometritis (CE) in 33 women with infertility, papillomavirus infection (PVI) persisting in the uterine cavity, and recurrent herpes-virus infection (Tapilskaya et al, 2022). The administration of alloferon and valacyclovir for 30 days resulted in elimination of HPV and lessened the severity of chronic endometritis (Tapilskaya et al, 2022).…”

“…In a study conducted by Tapilskaya et al, alloferon (Allokin-alpha) was evaluated in the complex treatment of virus-associated chronic endometritis (CE) in 33 women with infertility, papillomavirus infection (PVI) persisting in the uterine cavity, and recurrent herpes-virus infection (Tapilskaya et al, 2022). The administration of alloferon and valacyclovir for 30 days resulted in elimination of HPV and lessened the severity of chronic endometritis (Tapilskaya et al, 2022). Alloferon's clinical effects were also assessed in 59 patients with chronic Epstein-Barr virus infection (CEBVI) using Allokin-alpha.…”